{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:45:18Z","timestamp":1788414318377,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008129","name":"University of Burdwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2019\/001296"],"award-info":[{"award-number":["CRG\/2019\/001296"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["EEQ\/2021\/0594"],"award-info":[{"award-number":["EEQ\/2021\/0594"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/025(0243)\/2018-EMR-I"],"award-info":[{"award-number":["09\/025(0243)\/2018-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.intimp.2022.109521","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T01:25:56Z","timestamp":1670289956000},"page":"109521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma"],"prefix":"10.1016","volume":"114","author":[{"given":"Abhinandan","family":"Rej","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Paladhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrat","family":"Daripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit Kumar","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109521_b0005","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2022, CA: A Cancer Journal for Clinicians 72(1) (2022) 7-33.","DOI":"10.3322\/caac.21708"},{"issue":"10091","key":"10.1016\/j.intimp.2022.109521_b0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.intimp.2022.109521_b0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/jha2.394","article-title":"Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed\/refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"3","author":"Nastoupil","year":"2022","journal-title":"eJHaem"},{"issue":"3","key":"10.1016\/j.intimp.2022.109521_b0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/fon-2018-0388","article-title":"The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions","volume":"15","author":"Jurczak","year":"2018","journal-title":"Future Oncology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41392-020-0113-2","article-title":"Advances in targeted therapy for malignant lymphoma","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"12","key":"10.1016\/j.intimp.2022.109521_b0030","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1002\/cncr.11846","article-title":"Kyeong Kim, Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients","volume":"98","author":"Lee","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2022.109521_b0035","doi-asserted-by":"crossref","unstructured":"Y. He, W. Tao, D. Ji, W. Lu, Y. Xiong, G. Chen, RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis, Translational Cancer Research; Vol 10, No 5 (May 2021): Translational Cancer Research (2021).","DOI":"10.21037\/tcr-20-3123"},{"issue":"9880","key":"10.1016\/j.intimp.2022.109521_b0040","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2022.109521_b0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.intimp.2022.109521_b0050","doi-asserted-by":"crossref","DOI":"10.1097\/PPO.0000000000000444","article-title":"Advances in Treatment of Follicular Lymphoma","volume":"26","author":"Luminari","year":"2020","journal-title":"The Cancer Journal"},{"issue":"19","key":"10.1016\/j.intimp.2022.109521_b0055","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.intimp.2022.109521_b0060","doi-asserted-by":"crossref","first-page":"e10129","DOI":"10.1002\/btm2.10129","article-title":"Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin","volume":"4","author":"Pusuluri","year":"2019","journal-title":"Bioengineering & Translational Medicine"},{"key":"10.1016\/j.intimp.2022.109521_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071772","article-title":"Transforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma","author":"Timmins","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2022.109521_b0070","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood.V112.11.1551.1551","article-title":"Malignant B Cell-Derived TGF-\u03b2 Controls the Generation of TH1, TH17 and Treg Cells in the Tumor Microenvironment of B-Cell Non-Hodgkin Lymphoma (NHL)","volume":"112","author":"Yang","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.intimp.2022.109521_b0075","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood.V118.21.1586.1586","article-title":"TGF-\u03b2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL)","volume":"118","author":"Yang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2022.109521_b0080","doi-asserted-by":"crossref","unstructured":"Y. Ting Hee, J. Yan, D. Nizetic, W.-J. Chng, LEE011 and ruxolitinib: a synergistic drug combination for natural killer\/T-cell lymphoma (NKTCL), Oncotarget; Vol 9, No 61 (2018).","DOI":"10.18632\/oncotarget.25835"},{"issue":"4","key":"10.1016\/j.intimp.2022.109521_b0085","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.1002\/cti2.1270","article-title":"TGF-\u03b2-secreting regulatory B cells: unsung players in immune regulation","volume":"10","author":"Huai","year":"2021","journal-title":"Clinical & Translational Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10.1016\/j.intimp.2022.109521_b0095","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2022.109521_b0100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/cancers13030401","article-title":"TGF-\u03b2 in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment","volume":"13","author":"Angioni","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0105","first-page":"6315","article-title":"TGF\u03b2-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts, Nature","volume":"11","author":"Grauel","year":"2020","journal-title":"Communications"},{"issue":"7","key":"10.1016\/j.intimp.2022.109521_b0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/jir.2007.0009","article-title":"Transforming Growth Factor-\u03b2 Signaling in Normal and Malignant Hematopoiesis","volume":"27","author":"Isufi","year":"2007","journal-title":"Journal of Interferon & Cytokine Research"},{"issue":"5","key":"10.1016\/j.intimp.2022.109521_b0115","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41375-019-0420-1","article-title":"The role of TGF\u03b2 in hematopoiesis and myeloid disorders","volume":"33","author":"Bataller","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0120","article-title":"Prognostic Utility of Transforming Growth Factor Beta-1 in Diffuse Large Cell Non-Hodgkin Lymphoma, Journal of","volume":"4","author":"El-Hefni","year":"2015","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.immuni.2009.06.015","article-title":"Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo","volume":"31","author":"Tinoco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.109521_b0130","doi-asserted-by":"crossref","unstructured":"S.K. Hira, A. Rej, A. Paladhi, R. Singh, J. Saha, I. Mondal, S. Bhattacharyya, P.P. Manna, Galunisertib Drives Treg Fragility and Promotes Dendritic Cell-Mediated Immunity against Experimental Lymphoma, iScience 23(10) (2020) 101623.","DOI":"10.1016\/j.isci.2020.101623"},{"key":"10.1016\/j.intimp.2022.109521_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.852065","article-title":"Nanoscale Diamond-Based Formulation as an Immunomodulator and Potential Therapeutic for Lymphoma","volume":"13","author":"Paladhi","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.intimp.2022.109521_b0140","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1039\/C9TB02628B","article-title":"Studies on interaction potency model based on drug synergy and therapeutic potential of triple stimuli-responsive delivery of doxorubicin and 5-fluoro-2-deoxyuridine against lymphoma using disulfide-bridged cysteine over mesoporous silica nanoparticles","volume":"8","author":"Srivastava","year":"2020","journal-title":"Journal of Materials Chemistry B"},{"key":"10.1016\/j.intimp.2022.109521_b0145","article-title":"Doxorubicin loaded pH responsive biodegradable ABA-type Amphiphilic PEG-b-aliphatic Polyketal-b-PEG block copolymer for therapy against aggressive murine lymphoma, Nanomedicine: Nanotechnology","volume":"24","author":"Hira","year":"2020","journal-title":"Biology and Medicine"},{"issue":"2","key":"10.1016\/j.intimp.2022.109521_b0150","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Research"},{"key":"10.1016\/j.intimp.2022.109521_b0155","first-page":"504","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model, Comput Struct","volume":"13","author":"Yadav","year":"2015","journal-title":"Biotechnol J"},{"issue":"9","key":"10.1016\/j.intimp.2022.109521_b0160","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2014.84","article-title":"TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.intimp.2022.109521_b0165","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"Journal of Experimental Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2407-12-147","article-title":"Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.intimp.2022.109521_b0175","doi-asserted-by":"crossref","first-page":"21614","DOI":"10.18632\/oncotarget.4308","article-title":"Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients","volume":"6","author":"Serova","year":"2015","journal-title":"Oncotarget"},{"issue":"6832","key":"10.1016\/j.intimp.2022.109521_b0180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.intimp.2022.109521_b0185","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2022.109521_b0190","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2022.109521_b0195","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13402-014-0210-8","article-title":"Anti-tumor activity of the TGF-\u03b2 receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts","volume":"38","author":"Maier","year":"2015","journal-title":"Cellular Oncology"},{"key":"10.1016\/j.intimp.2022.109521_b0200","first-page":"4479","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug design, development and therapy"},{"issue":"9","key":"10.1016\/j.intimp.2022.109521_b0205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1470-2045(22)00446-6","article-title":"Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial","volume":"23","author":"Yamazaki","year":"2022","journal-title":"The Lancet Oncology"},{"issue":"9","key":"10.1016\/j.intimp.2022.109521_b0210","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1002\/cam4.3880","article-title":"Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma","volume":"10","author":"Harding","year":"2021","journal-title":"Cancer Medicine"},{"issue":"8","key":"10.1016\/j.intimp.2022.109521_b0215","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"13","key":"10.1016\/j.intimp.2022.109521_b0220","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.intimp.2009.09.008","article-title":"Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4\u20131BB","volume":"9","author":"Park","year":"2009","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.intimp.2022.109521_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106031","article-title":"Essential role of TNF-\u03b1 in gamma c cytokine aided crosstalk between dendritic cells and natural killer cells in experimental murine lymphoma","volume":"78","author":"Gupta","year":"2020","journal-title":"International Immunopharmacology"},{"issue":"12","key":"10.1016\/j.intimp.2022.109521_b0230","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jcyt.2022.07.012","article-title":"\u03b3c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1","volume":"24","author":"Singh","year":"2022","journal-title":"Cytotherapy"},{"issue":"988071","key":"10.1016\/j.intimp.2022.109521_b0235","article-title":"Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity","volume":"13","author":"Paladhi","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/j.intimp.2022.109521_b0240","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/eji.201242505","article-title":"Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response","volume":"43","author":"Hannesd\u00f3ttir","year":"2013","journal-title":"European Journal of Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Research"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0250","first-page":"61","article-title":"Role of Host Defense Mechanisms in the Antitumor Activity of Adriamycin and Daunomycin in Mice2","volume":"63","author":"Mantovani","year":"1979","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/j.intimp.2022.109521_b0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11605-021-05087-x","article-title":"TGF-\u03b2 Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Trebska-McGowan","year":"2022","journal-title":"Journal of Gastrointestinal Surgery"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922010062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:52:47Z","timestamp":1761587567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922010062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":51,"alternative-id":["S1567576922010062"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109521","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109521"}}